158 related articles for article (PubMed ID: 34987015)
21. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.
Gale RE; Hills R; Pizzey AR; Kottaridis PD; Swirsky D; Gilkes AF; Nugent E; Mills KI; Wheatley K; Solomon E; Burnett AK; Linch DC; Grimwade D;
Blood; 2005 Dec; 106(12):3768-76. PubMed ID: 16105978
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological Significance of Common Genetic Alterations in Patients With Acute Promyelocytic Leukemia.
Nath S; Bhattacharyya J; Chandra P; Saxena R; Sazawal S; Saikia KK
Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):54-57. PubMed ID: 32755558
[TBL] [Abstract][Full Text] [Related]
23. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
[TBL] [Abstract][Full Text] [Related]
24. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia].
Wu DP; Yan LZ; Yang L; Chen SN; Wu XJ; Liang JY
Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):907-10. PubMed ID: 18261272
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
26. [FLT3 and NPM1 gene mutations in patients with acute myeloid leukemias and the impact of FLT3-ITD mutations on the survival of patients with a normal karyotype].
Martynkevich IS; Gritsaev SV; Moskalenko MV; Ivanova MP; Aksenova VIu; Tiranova SA; Abdulkadyrov KM
Ter Arkh; 2010; 82(12):33-9. PubMed ID: 21516736
[TBL] [Abstract][Full Text] [Related]
27. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.
Loghavi S; Zuo Z; Ravandi F; Kantarjian HM; Bueso-Ramos C; Zhang L; Singh RR; Patel KP; Medeiros LJ; Stingo F; Routbort M; Cortes J; Luthra R; Khoury JD
J Hematol Oncol; 2014 Oct; 7():74. PubMed ID: 25281355
[TBL] [Abstract][Full Text] [Related]
28. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
29. [Clinical features and prognostic factors in adult acute myeloid leukemia patients with FLT3-ITD and CEBPA gene co-mutation].
Pei RR; Zhang RH; Yu JF; Jiang ZX; Sun H; Wan DM; Xie XS; Liu YF; Li T; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):297-301. PubMed ID: 32447933
[No Abstract] [Full Text] [Related]
30. [FLT3-ITD Mutation in Newly Diagnosed Patients with Acute Promyelocytic Leukemia].
Gong BF; Wang Y; Lin D; Wei H; Li W; Zhou CL; Liu BC; Liu KQ; Zhang GJ; Liu YT; Li Y; Wei SN; Gong XY; Zhao XL; Qiu SW; Gu RX; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1615-1621. PubMed ID: 28024465
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation.
Jiang A; Jiang H; Brandwein J; Kamel-Reid S; Chang H
Leuk Res; 2011 Apr; 35(4):492-8. PubMed ID: 20684989
[TBL] [Abstract][Full Text] [Related]
32. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
[TBL] [Abstract][Full Text] [Related]
33. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.
Gale RE; Green C; Allen C; Mead AJ; Burnett AK; Hills RK; Linch DC;
Blood; 2008 Mar; 111(5):2776-84. PubMed ID: 17957027
[TBL] [Abstract][Full Text] [Related]
34. Haematological & molecular profile of acute myelogenous leukaemia in India.
Sazawal S; Kumar B; Hasan SK; Dutta P; Kumar R; Chaubey R; Mir R; Saxena R
Indian J Med Res; 2009 Mar; 129(3):256-61. PubMed ID: 19491417
[TBL] [Abstract][Full Text] [Related]
35. The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse.
Kurosawa S; Yamaguchi H; Yamaguchi T; Fukunaga K; Yui S; Kanamori H; Usuki K; Uoshima N; Yanada M; Takeuchi J; Mizuno I; Kanda J; Okamura H; Yano S; Tashiro H; Shindo T; Chiba S; Tomiyama J; Inokuchi K; Fukuda T
Int J Hematol; 2020 Aug; 112(2):200-209. PubMed ID: 32495317
[TBL] [Abstract][Full Text] [Related]
36. Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene.
Yoo SJ; Park CJ; Jang S; Seo EJ; Lee KH; Chi HS
Leuk Lymphoma; 2006 Sep; 47(9):1788-93. PubMed ID: 17064989
[TBL] [Abstract][Full Text] [Related]
37. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
38. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
Callens C; Chevret S; Cayuela JM; Cassinat B; Raffoux E; de Botton S; Thomas X; Guerci A; Fegueux N; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Ferrand A; Sanz M; Chomienne C; Fenaux P; Dombret H;
Leukemia; 2005 Jul; 19(7):1153-60. PubMed ID: 15889156
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.
Kuwatsuka Y; Tomizawa D; Kihara R; Nagata Y; Shiba N; Iijima-Yamashita Y; Shimada A; Deguchi T; Miyachi H; Tawa A; Taga T; Kinoshita A; Nakayama H; Kiyokawa N; Saito AM; Koh K; Goto H; Kosaka Y; Asou N; Ohtake S; Miyawaki S; Miyazaki Y; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kobayashi S; Kitamura K; Sakaida E; Ogawa S; Naoe T; Hayashi Y; Horibe K; Manabe A; Mizutani S; Adachi S; Kiyoi H
Int J Hematol; 2018 Feb; 107(2):201-210. PubMed ID: 29027108
[TBL] [Abstract][Full Text] [Related]
40. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
